Reichman Melvin, Simpson Peter B
Lankenau Institute for Medical Research, Chemical Genomics Center, 100 Lancaster Ave, Wynnewood, PA, USA.
N8 Research Partnership, Manchester, UK.
Drug Discov Today. 2016 May;21(5):779-88. doi: 10.1016/j.drudis.2015.12.008. Epub 2015 Dec 29.
Open innovation in pharmaceutical R&D evolved from a triple helix of convergent paradigm shifts in academic, industrial and government research sectors. The birth of the biotechnology sector catalyzed shifts in location dynamics that led to the first wave of open innovation in pharmaceutical R&D between big pharma and startup companies. The National Institutes of Health (NIH) Roadmap was a crucial inflection point that set the stage for a new wave of open innovation models between pharmaceutical companies and universities that have the potential to transform the pharmaceutical R&D landscape. We highlight the attributes of leading protected open innovation models that foster the sharing of proprietary small molecule collections by lowering the risk of premature escape of intellectual property, particularly structure-activity data.
制药研发中的开放式创新源于学术、产业和政府研究部门三重螺旋式的趋同范式转变。生物技术行业的诞生催化了地点动态的转变，引发了大型制药公司与初创公司之间制药研发领域的第一波开放式创新。美国国立卫生研究院（NIH）路线图是一个关键的转折点，为制药公司与大学之间的新一轮开放式创新模式奠定了基础，这些模式有可能改变制药研发格局。我们强调了领先的受保护开放式创新模式的特点，这些模式通过降低知识产权尤其是构效数据过早泄露的风险，促进了专有小分子库的共享。
